Postoperative Acute Lung Injury Following Lobectomy for Non-Small Cell Lung Cancer: What Are the Risk Factors?

CHEST Journal ◽  
2017 ◽  
Vol 152 (4) ◽  
pp. A638
Author(s):  
Hyun Jung Kim ◽  
Chan-Hee Lee
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Acute Lung Injury ◽  
Lung Injury ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals A Case of Pemetrexed-Induced Acute Lung Injury in Non-small Cell Lung Cancer

2010 ◽  
Vol 5 (3) ◽  
pp. 401-402 ◽  
Author(s):  
Hye Ok Kim ◽  
Sung Yong Lee ◽  
Jae Jeong Shim ◽  
Kyung Ho Kang ◽  
Bong Kyung Shin
Keyword(s):  
Lung Cancer ◽  
Acute Lung Injury ◽  
Lung Injury ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

PCN199 Risk Factors of Treatment Delay Among NON-SMALL Cell LUNG Cancer (NSCLC) Patients in Louisiana

2021 ◽  
Vol 24 ◽  
pp. S56-S57
Author(s):  
Y. Zhang ◽  
M.C. Hsieh ◽  
E. Nauman ◽  
K. Callison ◽  
S. Tackett ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Delay ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

scholarly journals Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

Cancers ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 384 ◽  
Author(s):  
Ashley Hopkins ◽  
Anh-Minh Nguyen ◽  
Christos Karapetis ◽  
Andrew Rowland ◽  
Michael Sorich
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Body Mass ◽  
Risk Score ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
Severe Diarrhea

Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic regression with pooled individual participant data from seven clinical studies. A risk score was developed based on the count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight (<45 kg), female sex, and older age (≥60 years) were identified as major independent risk factors (p < 0.01). Each risk factor was associated with a two-fold increase in the odds of severe diarrhea, and this was consistent between individuals commenced on 40 mg or 50 mg afatinib. A simple risk score based on the count of these risk factors identifies individuals at lowest and highest risk (C-statistic of 0.65). Risk of severe diarrhea for individuals commenced on 40 mg afatinib ranged from 6% for individuals with no risk factors to 33% for individuals with all three risk factors.

Sign in / Sign up

Export Citation Format

Share Document